Overview:

This report analyzes promotional activity for key drugs competing in the disease area Chronic Pain for Q3, 2010. Geographic market includes North America (US only); number of total items circulating in the field during this period was 197; number of new items circulating in the field during this period was 90.

Drugs analyzed in this report:

Chronic Pain: Avinza (King), BuTrans (Purdue), Embeda (King), Exalgo (Mallinckrodt), Opana ER (Endo), Oxycontin (Purdue), Ryzolt (Purdue), Ultram ER (PriCara) Cancer Pain: Fenbora (Cephalon), Onsolis (Meda)

Scope:

Key messaging findings highlighting marketing and patient access, total # of items in field per drug, # of new items in field per drug versus previous items in field, messaging focus of new items per drug.

Overview:

This report analyzes promotional activity for key drugs competing in the disease area CINV for Q3, 2010. Geographic market includes North America (US only); number of total items circulating in the field during this period was 21; number of new items circulating in the field during this period was 11.

Drugs analyzed in this report:

Aloxi (Elsai/Helsinn), Cesamet (Meda), Emend (Merck), Sancuso (ProStrakan)

Scope:

Key messaging findings highlighting marketing, clinical data/development, and patient access, total # of items in field per drug, # of new items in field per drug versus previous items in field, messaging focus of new items per drug.

Overview:

This report analyzes promotional activity for key drugs competing in the disease area Diabetes for October 2010. Geographic market includes North America (US only); number of total items circulating in the field during this period was 497; number of new items circulating in the field during this period was 245.

Drugs analyzed in this report:

Insulins: Apidra (Sanofi-Aventis), Humalog (Lilly), Lantus (Sanofi-Aventis), Levemir (Novo Nordisk), Novolog (Novo Nordisk)
NonInsulins: Actos brands (Takeda), Byetta (Amylin, Lilly), Januvia/Janumet (Merck), Onglyza (BMS, Astra Zeneca), Symlin (Amylin), Victoza (Novo Nordisk)

Scope:

Key messaging findings highlighting marketing and clinical data/development, total # of items in field per drug, # of new items in field per drug versus previous items in field, messaging focus of new items per drug.

Overview:

This report analyzes promotional activity for key drugs competing in the disease area Female Contraceptives for Q3, 2010. Geographic market includes North America (US only); number of total items circulating in the field during this period was 102; number of new items circulating in the field during this period was 24.

Drugs analyzed in this report:

COCs: Loestrin 24 Fe/ Lo Loestrin 24 Fe (Warner Chilcott), Natazia (Bayer), Ortho Tri-Cyclen (Ortho McNeil), Yaz (Bayer)
Extended COCs: Lybrel (Pfizer), Seasonique/ LoSeasonique (Teva

Scope:

Key messaging findings highlighting patient access, marketing, total # of items in field per drug, # of new items in field per drug versus previous items in field, messaging focus of new items per drug.

Overview:

This report analyzes promotional activity for key drugs competing in the disease area Pulmonary Arterial Hypertension (PAH) for Q1, 2011. Geographic market includes North America (US only); number of total items circulating in the field during this period was 163; number of new items circulating in the field during this period was 121.

Drugs analyzed in this report:

Adcirca (United Therapeutics), Letairis (Gilead), Remodulin (United Therapeutics), Revatio (Pfizer), Tracleer (Actelion), Tyvaso (United Therapeutics), Valetri (Actelion), Ventavis (Actelion)

Scope:

Key messaging findings highlighting marketing and patient access, total # of items in field per drug, # of new items in field per drug versus previous items in field, messaging focus of new items per drug.

Overview:

This report analyzes promotional activity for key drugs competing in the disease area Overactive Bladder (OAB). Geographic market includes North America (US only); number of total items circulating in the field during this period was 70; number of new items circulating in the field during this period was 24.

Drugs analyzed in this report:

Detrol LA (Pfizer), Enablex (Novartis), Gelnique (Watson), Sanctura XR (Allergan), Toviaz (Pfizer), Vesicare (Astellas)

Scope:

Key messaging findings highlighting marketing, clinical data/development, and patient access, total # of items in field per drug, # of new items in field per drug versus previous items in field, messaging focus of new items per drug.

Overview:

This report analyzes promotional activity for key drugs competing in the disease area Psoriasis for Q4, 2010. Geographic market includes North America (US only); number of total items circulating in the field during this period was 163; number of new items circulating in the field during this period was 121.

Drugs analyzed in this report:

Biologic: Amevive (Astellas), Enbrel (Amgen/Pfizer), Humira (Abbott), Remicade (Centocor Ortho Biotech), Stelara (Centocor Ortho Biotech)
Topical: Clobex (Galderma), Olux/Olux-E (Galderma), Taclonex/Dovobet/Xamiol (Leo), Vectical (Galderma)

Scope:

Key messaging findings highlighting marketing, DTC, and patient access, total # of items in field per drug, # of new items in field per drug versus previous items in field, messaging focus of new items per drug.